Catalio Conversations

Catalio Capital Management
  • 0.0 (0)
  • Entrepreneurship

Welcome to Catalio Conversations! We spotlight founders & CEOs across innovative healthcare, AI & life sciences, who are building the next generation of disruptors in the space – from drug discovery and autonomous labs to clinical care & beyond. The future starts here.

Episodes

  1. 3 days ago

    How Clinical AI is Saving Lives with Suchi Saria – Founder & CEO of Bayesian Health

    Explore the future of healthcare with AI that could help hospitals catch life-threatening conditions before they turn critical! In this episode of Catalio Conversations, Martha Petrocheilos sits with Suchi Saria, founder and CEO of Bayesian Health, who reveals how combining cutting-edge AI with deep clinical integration is rewriting the rules of patient care – think a sepsis monitor that flags danger hours earlier and helps hospitals act before it’s too late. Suchi’s journey from academic researcher at Johns Hopkins, Stanford, and Harvard to healthcare entrepreneur offers a masterclass in turning breakthrough research into real-world impact. From Bayesian’s continuous AI monitor and EMR-integrated clinical intelligence layer to its landmark results in adoption and mortality reduction, this episode pulls back the curtain on what genuinely AI-powered healthcare looks like. And with the Coalition for Health AI helping set standards across the industry, Bayesian isn’t just promising the future – they’re building it. Perfect for healthcare leaders, AI enthusiasts, and anyone curious about the next frontier of medicine, this episode reveals the paradigm shifts redefining what’s possible in hospitals. Be here for the rare inside look into the biggest leap in healthcare AI –the next life-saving intervention might already be identified by an algorithm, waiting to change a patient’s outcome. Timestamped Summary: 00:00 - Introduction to Suchi Saria and the mission of Bayesian Health 01:01 - The personal story behind Suchi’s dedication to life-saving AI 01:30 - Transitioning from academia to building an impactful health tech company 02:16 - Filling the gap between AI research and bedside application 03:47 - Achieving FDA clearance for the first continuous AI sepsis monitor 04:37 - Challenges of integrating AI into busy hospital workflows 05:46 - Deep integration with electronic medical records and real-world deployment 07:12 - Building clinician trust and avoiding alarm fatigue 08:32 - Impact of AI systems on clinical outcomes and survival rates 09:24 - Real-life story demonstrating AI’s potential in sepsis detection 10:44 - The importance of medical AI solutions that truly drive action 11:55 - Expanding AI to other critical conditions beyond sepsis 12:23 - How hospitals prioritize use cases based on impact and cost 13:01 - The role of collaborative standards in AI safety and efficacy 14:13 - Differentiating between AI 'theater' and tools with real outcomes 15:07 - How AI will change the roles of doctors and nurses in future hospitals 16:28 - The hospital of the future: proactive, AI-enabled, less administratively burdened 17:23 - Myth-busting in healthcare AI adoption 17:46 - The potential of AI in managing clinical deterioration more broadly 18:10 - Closing remarks and the importance of trust in AI healthcare solutions

    19 min

  2. 9 Jun

    How AI Drug Discovery is Supercharging Pace of Innovation with Tom Miller Co-Founder & CEO of Iambic

    Explore the future of drug development with AI that could compress decades of research into just years! Joining us at Catalio Conversations is Tom Miller, co-founder of Iambic, where he reveals how combining cutting-edge neural models with high-throughput experimentation is rewriting the rules of pharmaceutical innovation – think a cancer drug designed, optimized, and FDA-approved in under two years! Tom's journey from Caltech professor to drug discovery entrepreneur – alongside co-founder Fred Manby – offers a masterclass in turning academic breakthroughs into real-world medicines. From Iambic's game-changing Neuroplexer model that predicts exactly how drugs bind to proteins, to their landmark cancer candidate IM1363, this episode pulls back the curtain on what genuinely AI-powered drug discovery looks like. And with strategic partnerships with Lundbeck, Revolution Medicines, and Takeda already in place, Iambic isn't just promising the future – they're building it. Perfect for life sciences leaders, AI enthusiasts, and anyone curious about the next frontier of medicine, this episode reveals the paradigm shifts redefining what's possible in pharma. Don't miss this front-row seat to the biggest leap in pharmaceutical history – the next blockbuster cancer drug might already be designed by an algorithm, waiting to save your life. Timestamped Summary: 00:00 - Introduction to Catalio Conversations and guest Tom Miller 00:29 - Tom’s journey from Caltech professor to drug innovator 01:28 - Collaboration with co-founder Fred Manby 01:55 - Balancing scientific integrity with entrepreneurial agility 02:21 - Lessons from early Iambic experiments 03:13 - AI prediction and high-throughput experimentation 03:43 - Defining drug targets and designing molecules 04:11 - Neuroplexer in predicting drug-protein binding 05:06 - Multi-property optimization in discovery 06:24 - Rapid development of cancer candidate IM1363 06:49 - AI reducing drug development timelines 07:16 - Industry impact of AI-designed medicines 07:59 - Partnerships with Lundbeck and Revolution Medicines 08:55 - Building credibility through collaborations 09:21 - Genuine AI transformation vs. superficial branding 09:45 - Scaling advantage of AI-powered discovery 10:36 - AI’s potential in biological complexity 11:31 - Future of AI in drug development 12:24 - Iambic’s identity: AI platform or drug company? 13:21 - Future goals for Iambic and industry impact 14:13 - Promising targets like transcription factors 14:42 - Closing remarks and encouragement for innovation

    15 min

  3. 6 May

    How Autonomous Labs are Revolutionizing Drug Discovery with Michelle Lee - Founder & CEO of Medra AI

    Unlock the future of drug discovery with AI-powered robots that could revolutionize science as we know it! Joining us at Catalio Conversations is Michelle Lee, CEO of Medra AI, where she reveals how combining AI & robotics is creating the world's most advanced autonomous labs – think 100 robots working overnight to accelerate cures for disease! Michelle’s journey from chemical engineering and AI research to leading Medra’s groundbreaking "physical AI scientists" offers a blueprint for turning science fiction into reality. Looking ahead, Michelle envisions a world where entire drug pipelines are fully autonomous, enabling any scientist to create life-changing medicines. Perfect for life sciences leaders, AI enthusiasts, as well as tech-curious or business-curious viewers eager to see what’s next, this episode reveals the seismic shifts that will define the next decade of scientific discovery. Don’t miss this glimpse into the autonomous labs of tomorrow – because the next genetic breakthrough could come from a robot, not a human. Timestamped summary: 0:03 - Introduction: Welcome to Catalio Conversations 0:31 - Michelle Lee's Journey: Discussing the realization of the need for AI and robotics in biology. 1:00 - Alpha Fold Inspiration: The impact of Alpha Fold 2 on Michelle's vision. 1:25 - Data Generation with Robotics: How robots can scale up experimentation. 1:53 - Cultural Values at Medra: Insights from Michelle's diverse experiences. 2:21 - Medra's Interdisciplinary Approach: Combining engineering, AI, and biology. 3:13 - Physical AI Scientists: Differentiating from traditional lab automation. 4:08 - Challenges in Data Generation: The need for more and better data. 5:00 - Robotics in Experimentation: Solving data quantity and quality issues. 5:54 - Real Lab Stories: How Medra improved data generation for a client. 7:09 - Overcoming Skepticism: Transitioning from industrial to physical AI. 8:00 - Early Challenges at Medra: Learning from initial business strategies. 9:25 - Partnership Model: Medra's collaborative approach with clients. 10:17 - Recognition by Genentech: Being named a partner in AI strategy. 11:05 - Building Trust: Importance of fast communication and transparency. 11:56 - Future of Labs: Vision for autonomous labs and their impact. 12:43 - Empowering Scientists: Enabling scientists to start their own companies. 13:10 - Quick Fire Questions: Myths and future bets in AI and life sciences. 14:05 - Conclusion: Closing remarks and invitation to subscribe.

    14 min
  • 3 Episodes

About

Welcome to Catalio Conversations! We spotlight founders & CEOs across innovative healthcare, AI & life sciences, who are building the next generation of disruptors in the space – from drug discovery and autonomous labs to clinical care & beyond. The future starts here.

Information

  • Creator
    Catalio Capital Management
  • Years Active
    2k
  • Episodes
    3
  • Rating
    Clean
  • Copyright
    © 2026 Catalio Capital Management
  • Provider